Varenicline Completed Phase 3 Trials for Tobacco Dependence / Cessation, Smoking Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00143325An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
NCT00143364A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
NCT00143286A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
NCT00143299A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
NCT00141167A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation
NCT00141206A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
NCT00282984Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking
NCT00285012Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
NCT00371813An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking
NCT00789074Use of Varenicline for 4-weeks Prior to Quitting
NCT00894166Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
NCT01184664Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)
NCT01206010Tailoring Varenicline to Individual Needs (TVIN Study)